Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,580 signal articles · 330 in last 24h · 112,379 total before filter · latest 48m ago
330last 24h
2137last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
AllMacro294Earnings1216M&A91Regulatory23Product13Analyst20
✕ clear all filtersticker: CVSSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Mizuho Raises CVS Health (CVS) Price Target on More Stable Policy Environment
Insider Monkey60d agoneutral
Mizuho Raises CVS Health (CVS) Price Target on More Stable Policy Environment

With an annual dividend yield of 2.65%, CVS Health Corporation (NYSE:CVS) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS), provides advanced health care from pharmacy services and health plans to health and wellness. On June 8, Mizuho upped its price target on […]

CVS Health (CVS) Price Target Boosted by $8 at Mizuho
Insider Monkey80d agoneutral
CVS Health (CVS) Price Target Boosted by $8 at Mizuho

With an annual dividend yield of 2.84%, CVS Health Corporation (NYSE:CVS) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS) provides advanced health care from pharmacy services and health plans to health and wellness. On May 20, Mizuho bumped up its price […]

CVS Health (CVS) Price Target Boosted by $1
Insider Monkey92d agoneutral
CVS Health (CVS) Price Target Boosted by $1

With an annual dividend yield of 2.88%, CVS Health Corporation (NYSE:CVS) is included among the 12 Best Blue Chip Dividend Stocks to Buy Now. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS) provides advanced health care from pharmacy services and health plans to health and wellness. On May 8, Wells Fargo analyst Stephen Baxter slightly raised […]